2-amino-1-butyl-1H-pyrrolo[2,3-b]quinoxaline-3-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-amino-1-butyl-1H-pyrrolo[2,3-b]quinoxaline-3-carbonitrile
• 英文别名: 2-amino-1-butylpyrrolo[3,2-b]quinoxaline-3-carbonitrile
• 化学式: C₁₅H₁₅N₅
• 分子量: 265.31
• InChiKey: OLICCRYPRZAUNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  80.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Inhibiting G Protein Coupled Receptor 6 Kinase Polypeptides
  申请人：Mayo Foundation for Medical Educational and Research

  公开号：US20140309185A1

  公开（公告）日：2014-10-16

  This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.

  这份文件涉及G蛋白偶联受体6激酶（GRK6）多肽的抑制剂，以及利用这些抑制剂治疗血液恶性肿瘤、炎症性疾病和自身免疫性疾病的方法和材料。
• BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS OF THEIR USE
  申请人：Institute at Lake Nona Sanford-Burnham Medical Research

  公开号：US20130245032A1

  公开（公告）日：2013-09-19

  According to the embodiments described herein, a tricyclic SUMOylation inhibitor compound is provided. In some embodiments, a method for inhibiting a SUMOylation enzyme in a cell is provided. Such a method may include administering a SUMOylation inhibitor compound to the cell. In some aspects, the SUMOylation enzyme is SUMO E1 or SUMO E2. In some aspects, the method may be used to inhibit a cancer cell in vitro (e.g., grown in culture) or in vivo (e.g., as part of a tumor in a subject). In other embodiments, a method for treating a cancer, degenerative diseases and viral infection is provided. Such a method may include administering an effective amount of a pharmaceutical composition to a subject having the cancer. The pharmaceutical composition may include a SUMOylation inhibitor compound. In some embodiments, the method for treating a disease may further comprise administering one or more DNA-damaging therapy in combination with administration of the pharmaceutical composition.

  根据所述实施例，提供了一种三环SUMO化抑制剂化合物。在某些实施例中，提供了一种在细胞中抑制SUMO化酶的方法。这样的方法可能包括向细胞中注射SUMO化抑制剂化合物。在某些方面，SUMO化酶是SUMO E1或SUMO E2。在某些方面，该方法可用于体外（例如在培养中生长）或体内（例如作为受体中的肿瘤的一部分）抑制癌细胞。在其他实施例中，提供了一种治疗癌症、退行性疾病和病毒感染的方法。这样的方法可能包括向患有癌症的受体中注射有效量的制药组合物。该制药组合物可能包括SUMO化抑制剂化合物。在某些实施例中，治疗疾病的方法可能进一步包括在注射制药组合物的同时注射一种或多种DNA损伤治疗方法。
• Inhibiting G protein coupled receptor 6 kinase polypeptides
  申请人：Mayo Foundation for Medical Education and Research

  公开号：US10252984B2

  公开（公告）日：2019-04-09

  This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.

  本文件涉及 G 蛋白偶联受体 6 激酶（GRK6）多肽的抑制剂以及使用这种抑制剂治疗血液恶性肿瘤、炎症疾病和自身免疫性疾病的方法和材料。
• US9045483B2
  申请人：——

  公开号：US9045483B2

  公开（公告）日：2015-06-02
• [EN] BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS BICYLIQUES ET TRICYCLIQUES D'ENZYMES DE SUMOYLATION ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CHEN YUAN

  公开号：WO2012064897A2

  公开（公告）日：2012-05-18

  According to the embodiments described herein, a tricyclic SUMOylation inhibitor compound is provided. In some embodiments, a method for inhibiting a SUMOylation enzyme in a cell is provided. Such a method may include administering a SUMOylation inhibitor compound to the cell. In some aspects, the SUMOylation enzyme is SUMO E1 or SUMO E2. In some aspects, the method may be used to inhibit a cancer cell in vitro (e.g., grown in culture) or in vivo (e.g., as part of a tumor in a subject). In other embodiments, a method for treating a cancer is provided. Such a method may include administering an effective amount of a pharmaceutical composition to a subject having the cancer. The pharmaceutical composition may include a SUMOylation inhibitor compound. In some embodiments, the method for treating a disease may further comprise administering one or more DNA-damaging therapy in combination with administration of the pharmaceutical composition.